Definium Therapeutics (DFTX) Operating Income (2019 - 2026)

Definium Therapeutics (DFTX) has 7 years of Operating Income data on file, last reported at -$59.2 million in Q1 2026.

• Quarterly Operating Income fell 84.15% year-over-year to -$59.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$193.4 million (down 69.81% YoY) and the FY2025 annual result came in at -$166.3 million, down 60.04% from the prior year.
• Operating Income slipped to -$59.2 million in Q1 2026 per DFTX's latest filing, from -$47.6 million in the prior quarter.
• Across five years, Operating Income topped out at -$13.9 million in Q4 2022 and bottomed at -$59.2 million in Q1 2026.
• The 5-year median for Operating Income is -$24.5 million (2024), against an average of -$28.8 million.
• Peak annual rise in Operating Income reached 62.53% in 2022, while the deepest fall reached 124.6% in 2022.
• Tracing DFTX's Operating Income over 5 years: stood at -$13.9 million in 2022, then sank by 59.75% to -$22.2 million in 2023, then slumped by 46.19% to -$32.5 million in 2024, then sank by 46.57% to -$47.6 million in 2025, then dropped by 24.47% to -$59.2 million in 2026.
• Per Business Quant, the three latest DFTX Operating Income figures stand at -$59.2 million (Q1 2026), -$47.6 million (Q4 2025), and -$45.7 million (Q3 2025).

Peer Comparison